Original Article

You have free access to this content

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)†

  1. Dennis M Black1,*,
  2. Ian R Reid2,
  3. Steven Boonen3,
  4. Christina Bucci-Rechtweg4,
  5. Jane A Cauley5,
  6. Felicia Cosman6,
  7. Steven R Cummings7,
  8. Trisha F Hue1,
  9. Kurt Lippuner8,
  10. Peter Lakatos9,
  11. Ping Chung Leung10,
  12. Zulema Man11,
  13. Ruvie Lou Maria Martinez4,
  14. Monique Tan4,
  15. Mary Ellen Ruzycky4,
  16. Guoqin Su4,
  17. Richard Eastell12

Article first published online: 23 JAN 2012

DOI: 10.1002/jbmr.1494

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 27, Issue 2, pages 243–254, February 2012

Additional Information

How to Cite

Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., Leung, P. C., Man, Z., Martinez, R. L. M., Tan, M., Ruzycky, M. E., Su, G. and Eastell, R. (2012), The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res, 27: 243–254. doi: 10.1002/jbmr.1494

Author Information

  1. 1

    University of California, San Francisco, CA, USA

  2. 2

    University of Auckland, Auckland, New Zealand

  3. 3

    Katholieke Universiteit Leuven, Leuven, Belgium

  4. 4

    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

  5. 5

    University of Pittsburgh, Pittsburgh, PA, USA

  6. 6

    Helen Hayes Hospital, West Haverstraw, NY, USA

  7. 7

    California Pacific Medical Center, San Francisco, CA, USA

  8. 8

    Bern University Hospital, Bern, Switzerland

  9. 9

    Semmelweis University Medical School, Budapest, Hungary

  10. 10

    Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China

  11. 11

    Centro Médico TIEMPO, Buenos Aires, Argentina

  12. 12

    University of Sheffield, Sheffield, UK

*University of California, San Francisco, Department of Epidemiology and Biostastistics, 185 Berry Street, Lobby 5, Suite 5700, San Francisco, CA 94107, USA.

  1. †

    For a Commentary on this article, please see Compston and Bilezikian (J Bone Miner Res. 2012;27:240–242. DOI: 10.1002/jbmr.1542).

Publication History

  1. Issue published online: 23 JAN 2012
  2. Article first published online: 23 JAN 2012
  3. Accepted manuscript online: 8 DEC 2011 10:50AM EST
  4. Manuscript Accepted: 25 OCT 2011
  5. Manuscript Revised: 20 OCT 2011
  6. Manuscript Received: 13 AUG 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (340K)

References

  • 1
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18): 1809–22.
  • 2
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041): 1535–41.
  • 3
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280(24): 2077–82.
  • 4
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14): 1344–52.
  • 5
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5): 333–40.
  • 6
    Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8): 1241–9.
    Direct Link:
  • 7
    Black D, Schwartz A, Ensrud K, Ryback-Feiglin A, Gupta J, Lombardi A, Wallace R, Levis S, Quandt S, Satterfield S, Cauley J, Cummings S. A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term EXtension (FLEX). J Bone Miner Res. 2004; 19: S45(Abstract).
  • 8
    Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM, FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010; 25(5): 976–82.
    Direct Link:
  • 9
    Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008; 19(3): 365–72.
  • 10
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10): 1479–91.
    Direct Link:
  • 11
    Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305(8): 783–9.
  • 12
    Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011; 22(2): 373–90.
  • 13
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25(11): 2267–94.
    Direct Link:
  • 14
    Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC. Fracture Intervention Trial Steering Committee, HORIZON Pivotal Fracture Trail Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362(19): 1761–71.
  • 15
    Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364(18): 1728–37.
  • 16
    Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24(6): 1095–102.
    Direct Link:
  • 17
    Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95(12): 5258–65.
  • 18
    Food and Drug Administration. September 9, 2011: joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting announcement [Internet]. Available from: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm262477.htm. Accessed 2011 October 19.
  • 19
    Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR. Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999; 14(1): 90–101.
    Direct Link:
  • 20
    Melton LJ 3rd, Wenger DE, Atkinson EJ, Achenbach SJ, Berquist TH, Riggs BL, Jiang G, Eastell R. Influence of baseline deformity definition on subsequent vertebral fracture risk in postmenopausal women. Osteoporos Int. 2006; 17(7): 978–85.
  • 21
    Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR. Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res. 1995; 10: 890–902.
    Direct Link:
  • 22
    Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 2008; 139(1): 32–40.
  • 23
    Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996; 91: 473–89.
  • 24
    Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010; 95(9): 4380–7.
  • 25
    Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med. 2000; 160(1): 77–85.
  • 26
    Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998; 128(10): 793–800.
  • 27
    Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285(3): 320–3.
  • 28
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24): 2927–38.
  • 29
    Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM. After 3 years of IV zoledronic acid administration, who is at highest risk for subsequent vertebral fractures and who should remain on treatment? J Bone Miner Res. 2011; 26( Suppl 1). Available at: http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006478-147&terms= [accessed 2011 December 22].
  • 30
    Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009; 94(2): 538–44.
  • 31
    McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol. 2009; 114(5): 999–1007.
  • 32
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-Term Extension. J Bone Miner Res. 2004; 19(8): 1259–69.
    Direct Link:
  • 33
    Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002; 137(11): 875–83.
  • 34
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005; 353(6): 555–65.
  • 35
    Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43(2): 222–9.
  • 36
    Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res. 2009; 24(3): 389–97.
    Direct Link:
View Full Article (HTML) Get PDF (340K)